Bioplus Acquisition (BIOS) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BIOS Annual Balance Sheets →
The balance sheet data below highlights changes in Bioplus Acquisition's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2023)
(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Assets
Cash & cash equivalent0.00
Cash & Short-term Investments0.00
Prepaid Expense, Current AS0.19
Total Current Assets0.20
Prepaid Expense, Noncurrent, Total PR0.00
Other Assets, Noncurrent138.00
Total Assets138.63
Liabilities
Accrued Liabilities, Current AC0.41
Bank Overdrafts SH0.25
Other Liabilities, Current1.32
Total Current Liabilities1.98
Total Long-term Debt0.00
Other liabilities, Noncurrent14.80
DeferredUnderwritingFeePayableNoncurrent9.80
Total Liabilities16.78
Stockholders' Equity
Common Stock Value0.00
Retained Earnings / Accumulated Deficit-16.58
Other Equity-138.43
Common Stockholder's Equity-155.02
Non-controlling interests & other138.43
Total Stockholder's Equity-16.58
Liabilities & Stockholder's Equity138.63
4 historic quarters locked

Sign in to unlock the full Bioplus Acquisition balance sheet history.

About Bioplus Acquisition Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-23-212329

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.